The symposium is organized jointly by the Medicinal Chemistry Section of the Swedish Pharmaceutical Society and ENABLE, one of the projects in the Innovative Medicines Initiative ND4BB, to showcase future opportunities for antibiotic drug discovery in a stimulating environment. It is also designed to provide plenty of opportunities to meet other delegates, renew friendships and foster new contacts.
Please circulate this information widely in your networks.
Who should attend:
This symposium should be highly interesting for scientists, and representatives from SMEs and the pharmaceutical industry working in the field of antibacterial drug discovery. The aims are to look into the future, at where and how new antibiotics will be discovered, and to discuss the challenges that need to be addressed in developing them. The lectures will be given by leading international scientists in the field. There will also be a poster session where we encourage scientists and company representatives to present and pitch their latest
The following will be covered:
- Finding new chemical entities for antibacterials
(Karen Bush, USA; Gerry Wright, Canada; Roger Linington, Canada)
- Alternatives to traditional antibiotics
(Mike Pucci, USA; Bob Hancock, Canada)
- Gram negative antibacterial entry
(Malcolm Page, Switzerland; Mike Dawson, UK)
- Antibacterial resistance
(Fernando Baquero, Spain; Tim Walsh, UK; Patrice Courvalin, France)
- Economics and policy of antibacterial drug discovery & development
- Industry experience of developing antibiotics
(Steve Baker, USA; Erin Duffy, USA; Ruben Tommasi, USA)
There will also be a poster session and we welcome abstracts for consideration.
Scientific and organizing committee
Anders Karlén, Uppsala University, Uppsala, Sweden; Cecilia Nilsson, Uppsala University, Uppsala, Sweden; Åsa Rosenquist, Medivir, Sweden; Mikael Elofsson, Umeå University, Umeå, Sweden; Jan-Erik Nyström, Alveiro LifeScience, Stockholm, Sweden; Robert Stavenger, Glaxo Smith Kline Research and Development Ltd, USA; Diarmaid Hughes, Uppsala University, Uppsala, Sweden; Claire Skentelbery, European Biotechnology Network aisbl, Brussels, Belgium; Frederik Deroose, Asclepia, Belgium; Malcolm Page, Basel University, Switzerland; Angela Wittelsberger, Innovative Medicines Initiative, Belgium; Eric Bacque, Sanofi-Aventis Research and Development, France; Carlos Vaca Falconi, Swedish Academy of Pharmaceutical Sciences, Stockholm, Sweden.
The symposium will be held at IVA Conference Center in Stockholm, Sweden, on 14-15 September, 2016. The program starts at 09.15 hrs the first day with registration and coffee from 08.00 hrs. The program ends on Thursday the 15th at approximately 16.00 hrs.
The participation fee for early registration is 2000 SEK for Academy (1000 SEK for students) and 4000 SEK for Industry. The registration fee after August 15 will be 2500 SEK for Academy (1500 SEK for students) and 5000 SEK for industry.The fee includes documentation, a certificate, coffee and lunch. All prices are excluding VAT.
For information about our cancellation policy, cancellation insurance and VAT, please see our home page, www.lakemedelsakademin.se
Register at lakemedelsakademin.se/antibiotics
Early registration is recommended!
Flyer symposium announcement